GUFIC BIOSCIENCES LTD. - 509079 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jayesh P Choksi & PACs GUFIC BIOSCIENCES LTD. - 509079 - Intimation For Receipt Of Share Certificate From M/S. Selvax Pty Limited ('Selvax') For Allotment Of 13,07,000 Ordinarily Fully Paid Up Equity Shares
This is in continuation to our earlier communication vide letter dated April 19, 2022 with regard to signing of Equity Subscription Agreement with M/s. Selvax Pty Limited ('Selvax'), a biotechnology company based in Perth, Western Australia, for subscription of its equity shares. We would like to update you that as per the terms of the aforesaid Agreement, Selvax have issued 13,07,000 (Thirteen Lakhs And Seven Thousand) ordinarily fully paid up equity shares to the Company at a total consideration of USD 100,000/- and a share certificate dated May 30, 2022 to this effect, have been issued by Selvax to the Company, today. GUFIC BIOSCIENCES LTD. - 509079 - Proposed Sale Of Shares Of The Company By The Promoter In The Open Market For Achieving Minimum Public Shareholding
In accordance with the requirements of Rules 19(2)(b) and 19A of the Securities Contracts (Regulations) Rules, 1957 and Regulation 38 of the SEBl (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para 2(a) and Para (3) of the SEBI Circular No. SEBl/HO/CFD/CMD/CIR/P/43/2018 dated February 22, 2018 ("the Circular'''') in connection with manner of achieving minimum public shareholding, we wish to inform that since the promoter shareholding is 75.48% of the total equity shareholding of the Company i.e. more than the prescribed limit of 75%, Mr. Jayesh P. Choksi, Promoter of the Company intends to sell 4,68,000 equity shares of his shareholding, which constitutes to around 0.48% of the total equity shareholding of the Company having face value of Re. 1/- each, the details of which is enclosed herewith. GUFIC BIOSCIENCES LTD. - 509079 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24(A) of the Securities And Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, enclosed herewith is the Annual Secretarial Compliance Report of the Company issued by M/ s. Manish Ghia & Associates, Practicing Company Secretaries, Mumbai, for the financial year ended March 31, 2022. Kindly take the same on record. GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
This is in continuation to our communication dated May 23, 2022 on Earning Conference Call and pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, written transcript of the said call held on May 23, 2022 at 4:30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://gufic.com/Notice/Transcript%20of%20Q4%20Earning%20Call.pdf Kindly take the same on record. GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) read with Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) as per the details enclosed herewith. GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed herewith the copies of Newspaper published today in Business Standard (All Edition in English language) and Mumbai Lakshwadeep (Mumbai Edition in Marathi language) in accordance with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time ('IEPF Rules'), inviting attention of concerned shareholders to submit their claims in respect of unclaimed dividends of the Company for last seven consecutive years failing which their shares would be transferred to IEPF Authority in accordance with Section 124(6) of the Companies Act, 2013 and rules made thereunder. GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the Earnings Conference Call held on May 23, 2022 at 4:30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://gufic.com/Notice/AUDIORECORDING_23052022.mp3 Written transcript of the same will be submitted in due course. Kindly take the same on record. GUFIC BIOSCIENCES LTD. - 509079 - Corporate Action-Board approves Dividend
In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Friday, May 20, 2022, inter alia, recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the Financial Year ended March 31, 2022, subject to the approval of the Shareholders at the ensuing Annual General Meeting. GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Outcome for Outcome Of The Board Of Directors Meeting Held On Friday, May 20, 2022
In compliance with Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations') (including any statutory modification(s), amendment(s) and re-enactment(s) thereof), this is to inform that the Board of Directors of the Company at its Meeting held today i.e. Friday, May 20, 2022, inter alia, considered and approved the following: 1. The Audited Financial Results of the Company for the Quarter and Financial Year ended March 31, 2022 along with the Auditors Report. 2. Recommended Dividend @ 10% i.e. Re. 0.10 per equity share (Face Value of Re. 1/- each) for the Financial Year ended March 31, 2022, subject to the approval of the Shareholders at the ensuing Annual General Meeting.